ZVSA (ZyVersa Therapeutics) Market Cap : $1.81 Mil (As of Mar. 23, 2025)

View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ZyVersa Therapeutics's share price for the quarter that ended in Sep. 2024 was $2.4. ZyVersa Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 1.07 Mil. Therefore, ZyVersa Therapeutics's market cap for the quarter that ended in Sep. 2024 was $2.58 Mil.

ZyVersa Therapeutics's quarterly market cap declined from Mar. 2024 ($6.26 Mil) to Jun. 2024 ($3.14 Mil) and declined from Jun. 2024 ($3.14 Mil) to Sep. 2024 ($2.58 Mil).

ZyVersa Therapeutics's annual market cap increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($14.29 Mil) but then declined from Dec. 2022 ($14.29 Mil) to Dec. 2023 ($3.65 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ZyVersa Therapeutics's Enterprise Value for Today is $-1.32 Mil.

ZyVersa Therapeutics Market Cap Historical Data

The historical data trend for ZyVersa Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics Market Cap Chart

ZyVersa Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Market Cap

14.29

3.65

ZyVersa Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Market Cap	Get a 7-Day Free Trial										5.62	3.65	6.26	3.14	2.58

Competitive Comparison of ZyVersa Therapeutics's Market Cap

For the Biotechnology subindustry, ZyVersa Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Market Cap falls into.

ZyVersa Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ZyVersa Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$9	*	0.405
	=	$3.65

ZyVersa Therapeutics's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )	=	Share Price (Q: Sep. 2024 )	*	Shares Outstanding (EOP) (Q: Sep. 2024 )
	=	$2.4	*	1.074
	=	$2.58

ZyVersa Therapeutics (NAS:ZVSA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

ZyVersa Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

ZyVersa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326

Website

https://www.zyversa.com

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Executives

Pablo A. Guzman	officer: Chief Medical Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover	director, officer: Chief Executive Officer	108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr.	officer: Chief Scientific Officer	C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe	officer: Chief Financial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere	officer: Chief Commercial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park	director	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd.	10 percent owner	4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones	director, officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor	director, officer: Chief Executive Officer	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp.	10 percent owner	88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880